Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Copper Histidinate→

Copper Histidinate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
12561-67-0
Molecular formula
C12H16CuN6O4
Molecular weight
371.84 g/mol
Drug class
Copper replacement agentcopper–histidine complex for parenteral supplementation
Mechanism of action
Provides bioavailable copper for cellular copper-dependent enzyme systems. Copper is required for normal activity of cytochrome c oxidase, lysyl oxidase, dopamine beta-hydroxylase and other cuproenzymes; replacement addresses systemic copper deficiency due to impaired transport.
Indications / reported uses
  • Treatment of paediatric patients with Menkes disease, including presymptomatic and symptomatic infants, under the product-specific copper histidinate indication; early initiation is important and use is specialist-directed

Sources: US DailyMed — ZYCUBO (copper histidinate) · NLM MeSH — Copper histidinate · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Copper replacement agent; copper–histidine complex for parenteral supplementation

Mechanism of action

Provides bioavailable copper for cellular copper-dependent enzyme systems. Copper is required for normal activity of cytochrome c oxidase, lysyl oxidase, dopamine beta-hydroxylase and other cuproenzymes; replacement addresses systemic copper deficiency due to impaired transport.

General use cases

  • Treatment of paediatric patients with Menkes disease, including presymptomatic and symptomatic infants, under the product-specific copper histidinate indication; early initiation is important and use is specialist-directed

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Copper Histidinate Environmental Risk Assessment (ERA) (the Copper Histidinate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.